^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor a positive breast cancer
Published date:
02/17/2021
Excerpt:
...the effect of specific PDGF receptor (PDGFR) inhibitors on ER-α+ breast cancer cells was investigated...In addition, the two PDGFR inhibitors were revealed to significantly inhibit cell growth...PDGFR inhibitors, including sunitinib and ponatinib, should be applied effectively to treat ER-α+ breast cancer.
DOI:
10.3892/ol.2021.12555
